Preferred Label : Mutant-selective EGFR Inhibitor TAS3351;
NCIt synonyms : EGFR Inhibitor TAS3351; EGFR Mutant-selective Inhibitor TAS3351;
NCIt definition : A fourth-generation, orally bioavailable, mutant-selective, epidermal growth factor
receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration,
mutant-selective EGFR inhibitor TAS3351 targets, binds to, and inhibits the activity
of various EGFR common mutant forms, such as the exon 19 deletion (ex19del) or the
L858R point mutation, with or without the resistance mutations T790M and/or C797S,
while sparing wild type EGFR activity. This prevents EGFR-mediated signaling, induces
cell death and inhibits tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor
tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation
and tumor vascularization. Compared to other EGFR inhibitors, TAS3351 inhibits EGFR
with T790M and C797S resistance mutations.;
Molecule name : TAS-3351; TAS 3351;
NCI Metathesaurus CUI : CL1907126;
Origin ID : C200314;
UMLS CUI : C5854516;
Semantic type(s)
- concept_is_in_subset
- has_target
